developing Tomorrow's innovative diagnostics
Hummingbird is harnessing the predictive power of blood-borne miRNAs to provide insights into human health and disease. Analysis of miRNAs with Hummingbird’s platform holds the potential for early disease detection, disease-specific prognostics, treatment response prediction, and the development of patient-centric therapies.
miRNA-based DIAGNOSTICS from blood
UPDATES ON THE LATEST DEVELOPMENTS
Explore our ground-breaking pipeline of proprietary, miRNA-based diagnostic tests from blood.
Hummingbird Diagnostics publishes study of miRisk as a predictor of immunotherapy efficacy in advanced-stage NSCLC.
Learn more about genomic biomarkers and read publications from the biomarker field.